TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05848973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Description: The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Description: The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
Study: NCT04777474

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced contact endoscopy
Description: The study subjects will undergo enhanced contact endoscopy - studied imaging technique

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Narrow band imaging
Description: The study subjects will undergo narrow band imaging - comparator procedure

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMAGE1S imaging
Description: The study subjects will undergo IMAGE1S imaging - comparator procedure
Study: NCT05989295

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic LRa05
Description: treatment about 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic LRa05
Description: treatment about 12 weeks
Study: NCT05943015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled intravenous analgesia
Description: Afterward of the operation, patients will be treated with patient-controlled analgesia with intravenous tramadol, with 20 mg bolus 20 minutes lock time, 4-hour limit 100 mg and 24-hour limit 400 mg
Study: NCT05465434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Supplement
Description: Zinc sulphate 50 mg
Study: NCT05145400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab :10 mg/kg intravenous will be administered in cycle 1-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR \> 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
Study: NCT05031429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Limited Eating
Description: Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
Study: NCT06204601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education According to Meleis' Transitional Theory to Patients With Pacemaker
Description: Patients in the experimental group will be trained according to Meleis's Transition Theory.
Study: NCT05979870

Intervention type: PROCEDURE
Intervention: Valvuloplasty,
Description: Choice of type of intervention decided on a multidisciplinary conference

Intervention type: PROCEDURE
Intervention: Valvuloplasty,
Description: Choice of type of intervention decided on a multidisciplinary conference

Intervention type: PROCEDURE
Intervention: Valvuloplasty,
Description: Choice of type of intervention decided on a multidisciplinary conference

Intervention type: PROCEDURE
Intervention: Valvuloplasty,
Description: Choice of type of intervention decided on a multidisciplinary conference
Study: NCT06394817

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05902780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Bupivacaine injection
Description: - Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Dexmedetomidine Injection
Description: - Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
Study: NCT05934110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-120/40
Description: EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID).
Study: NCT05165836

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plane block without Dexmedetomidine group
Description: Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane block with Dexmedetomidine group
Description: Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
Study: NCT05820594

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intradermal BCG (bacillus calmette-guerin) vaccine AJV
Description: Participants will receive a one off dose of BCG (bacillus calmette-guerin) Vaccine AJV which contains the Danish Strain of Mycobacterium bovis BCG at a dose of 6 - 24 x 105 CFU (three times the standard dose). This will be injected intradermally into the upper deltoid region.
Study: NCT05397275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation+breathe exercises
Description: progressive muscle relaxation+breathe exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathe exercises
Description: breathe exercises
Study: NCT05806476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: 1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: 1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
Study: NCT05631834

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic epidurale
Description: Epidurale Perioperative infusion of Ropivacaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: erector spinae interfascia Perioperative infusion of Ropivacaine
Study: NCT05934110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR orlistat 120 mg
Description: MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orlistat 120 mg,
Description: Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-60/20
Description: Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)
Study: NCT05806476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: 1.75mg / kg body mass of caffeine x 3 times a day during the run-in days and 3mg / body mass of caffeine once on the experimental days
Study: NCT05934110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)
Study: NCT06176846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality Exergaming Program
Description: Oculus Quest 3 glasses will be used as hardware for the IVR exergame program, and Boxing, HIIT, Combat, Sculpt and Dance, among the Fit-XR games that offer virtual reality experience for fitness, will be selected according to the physical fitness level of the subjects and personalized multicomponent ( balance, strength, agility, endurance) IVR exergame program will be created. The exercise program is limited to 25-30 minutes a day and will be applied 2 days a week for 8 weeks in the clinic under the supervision of a physiotherapist. The exergaming program will be progressed according to the difficulty level, duration and technical characteristics of the games.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise Program
Description: In the home-based exercise program, a personalized multicomponent (balance, strength, agility, endurance) exercise program will be applied according to the physical fitness level of the subjects. The exercises will progress by increasing the difficulty level and number of repetitions of the exercises. An e-brochure will be given to the subjects for the exercises, the exercises will be shown to the subjects on the 1st day, and exercise control will be carried out in the 1st week and the 4th week.
Study: NCT05806476

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo
Description: 1.75mg / kg body mass of microcrystalline cellulose x 3 times a day during the run-in days and 3mg / body mass of microcrystalline cellulose once on the experimental days
Study: NCT05834270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single dose tamsulosin 0.4mg
Description: Single dose tamsulosin 0.4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double dose tamsulosin 0.4mg
Description: Double dose tamsulosin 0.4mg
Study: NCT05496543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: All acupoints will be routinely sterilized at first. After the insertion of the needles, manipulations of lifting, twirling, and thrusting are performed on all needles to reach de qi, which is a sensation typically associated with needling including soreness, numbness, swelling, heaviness, and other feelings. This is considered to be an important component of the therapeutic effect of acupuncture.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham acupuncture
Description: The placebo needles chosen for this study are flat-tipped needles without a tip, which could not be pierced into the skin. In the meanwhile, an external patch device will fix the needles, which are visually pierced into the skin. After the treatment, the acupuncturist will press the acupuncture point with a dry cotton ball so that the patient can feel the pulling out of the needle.
Study: NCT06018974

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yetitablet gaming
Description: Playing digital games like bowling, memory games, coordination games ect. with the Yetitablet.
Study: NCT06514690

Intervention type: OTHER
Intervention: Sedation
Description: Different degrees of intravenous sedation according to the Ramsay scale

Intervention type: OTHER
Intervention: Sedation
Description: Different degrees of intravenous sedation according to the Ramsay scale
Study: NCT05833412

Intervention type: DIAGNOSTIC_TEST
Intervention: Septicyte Rapid ®
Description: SeptiCyte RAPID is based on the measurement of two gene expression biomarkers in peripheral blood (PLAC8 and PLA2G7) using quantitative reverse transcription-polymerase chain reaction (RT-qPCR). Based on the results obtained in 1 hour from whole blood (100 mcl), the device issues a report with a sepsis probability scale according to 4 bands (1 low probability, 2-3 intermediate probability and 4 high probability).

Intervention type: DIAGNOSTIC_TEST
Intervention: FilmArray® blood culture identification (BCID2®)
Description: After 6 to 8 hours of blood culture incubation, BCID2 will be performed on each of the 4 bottles. The BCID2 assay is an approved molecular test for the direct identification of pathogens causing bloodstream infections from blood cultures. The BCID2 Panel analyzes 43 targets associated with bloodstream infections, including Gram-negative bacteria, Gram-positive bacteria, yeasts and 10 antimicrobial resistance genes, all with a single test and with results available in approximately one hour from the blood culture. In addition, the BCID2® Panel menu includes seven additional resistance genes, including carbapenemases, colistin resistance genes and a MREJ assay that enables more speciﬁc MRSA identiﬁcation.
Study: NCT03544489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-ICD Intervention
Description: Home walking 3 days/week x 12 weeks
Study: NCT06155058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SYREBO
Description: Serial ADL training of upper extremities with robotic aid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Mirror Method
Description: Serial ADL training of upper extremities assisted by physical therapist
Study: NCT04483635

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly oral dose of placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Weekly oral dose of Vitamin D
Study: NCT04814030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Transarterial hepatic chemoembolization and FOLFOX-based infusion
Study: NCT06394349

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP+308nm
Description: PRP+308nm

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: NS+308nm
Description: NS+308nm
Study: NCT06309927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operative hysteroscopy (by tissue removal device)
Description: Surgical evacuation of the uterine cavity using the Truclear Mini-Elite hysteroscopic tissue removal device
Study: NCT06493175

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Application of large language model in emergency chest pain triage.
Description: The large language model MedGuide-V5 is able to quickly extract key information from a patients description, and by analyzing these descriptions, it provides physicians with a possible initial diagnosis to help them quickly prioritize the treatment of patients.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: According to the normal procedures to receive medical treatment
Description: After the artificial intelligence system evaluation, the patients will receive the diagnosis and treatment according to the normal procedure. The overall time of artificial triage, the triage of patients, and other data will be recorded. Patient visits should not be delayed by the use of artificial intelligence systems for evaluation.
Study: NCT05173844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SleepFix mobile application
Description: Digital behavioural therapy (dBTi) mobile application SleepFix® is specifically designed to treat insomnia and has been shown to be engaging and clinically efficacious.
Study: NCT05576298

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin degludec injection, RD15003
Description: single dose, s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin degludec injection, RD15003
Description: single dose, s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin degludec, Tresiba
Description: single dose, s.c. injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin degludec, Tresiba
Description: single dose, s.c. injection
Study: NCT05940064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Polatuzumab Vedotin, Rituximab
Description: Drug: Zanubrutinib, Polatuzumab Vedotin and Rituximab Zanubrutinib（Z）160 mg bid po Day 1-21; Polatuzumab Vedotin（P）1.8 mg/kg ivgtt D1; Rituximab（R）375 mg/m\^2 ivgtt D1
Study: NCT06071598

Intervention type: OTHER
Intervention: Surgical specimens of CRC-affected patients
Description: Specimens of CRC-affected patients will be collected during the surgery, without other risks for the patients, since we will use only material left after pathologist analysis
Study: NCT04973891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin combined with metformin
Description: Canagliflozin, a novel glucose-lowering medication, has been shown to have positive effects on reducing body weight, blood pressure and cardiovascular events.~Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin, a classical and common insulin sensitizer that can reduce both hyperinsulinemia and hyperandrogenemia, is widely used for patients with PCOS.
Study: NCT06193694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Formal coaching program followed by the Coaching Fidelity Tool, to be taken by the study group after program completion contains 12 questions, predominantly multiple choice and yes/no, although there is one question that requires a short answer as well as a place to write additional comments. These questions are meant to elicit responses about their experience with their assigned coach during their one-on-one coaching sessions.
Study: NCT05190744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB
Description: 500mg twice daily (BID) followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB
Description: 500mg twice daily (BID) followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB
Description: 500mg twice daily (BID) followed by 1000mg BID. The dose of PB inducing the maximal increase in urine osmolality will be continued for up to three months providing that no side effects are observed including clinical and laboratory surveillance.